Vistagen reports second quarter financial results and provides corporate update

South san francisco, calif.--( business wire )--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today reported financial results for its fiscal year 2023 second quarter ended september 30, 2022 and provided a corporate update.
VTGN Ratings Summary
VTGN Quant Ranking